← 홈

림프종

650개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-12 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 650개
CGTBiologicstaleWugen, Inc.Preclinical

Genetic: WU-CART-007 (Genetic: WU-CART-007)

T-cell Acute Lymphoblastic Leukemia; T-cell Lymphoblastic Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
AntibodystaleChangchun GeneScience Pharmaceu…Phase 1

Gentulizumab (Gentulizumab)

Solid Tumor; Non-Hodgkin Lymphoma · Solid Tumor

#SolidTumor#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleInstitut für Klinische Krebsfor…Phase 2

Glofitamab as Consolidation therapy (Glofitamab as Consolidation therapy)

Relapsed /Refractory DLBCL · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleInstitut für Klinische Krebsfor…Phase 2

Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy (Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy)

Relapsed /Refractory DLBCL · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
ADCBiologicstaleRochePhase 2

Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy (Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy)

Aggressive B-Cell Lymphoma · Aggressive B-Cell Lymphoma

#AggressiveB-CellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleRochePhase 2

Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy (Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy)

Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleRochePhase 2

Glofitamab; Polatuzumab vedotin; Zuberitamab; Cyclophosphamide; Doxorubicin; Prednisone (Glofitamab; Polatuzumab vedotin; Zuberitamab; Cyclophosphamide; Doxorubicin; Prednisone)

DLBCL - Diffuse Large B Cell Lymphoma; Chemo-free Therapy · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
CGTBiologicstaleChinese PLA General HospitalPhase 1

GoFast CD19 CAR T Cells (GoFast CD19 CAR T Cells)

Relapsed or Refractory Large B-cell Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 1

HDMP + rituximab as a means of debulking prior to initiating venetoclax. (HDMP + rituximab as a means of debulking prior to initiating venetoclax.)

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · Chronic Lymphocytic Leukemia or Small Ly

#ChronicLymphocyticLeukemiaorSmal#Antibody#Phase1#항체#면역항체+2
효능 ORR 1%임상시험 1상태 RECRUITING
ADCBiologicstaleOu Bai, MDPhase 2

Hi-miniCHOP +orelabrutinib (Hi-miniCHOP +orelabrutinib)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleOu Bai, MDPhase 2

HiMTO (HiMTO)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

High-dose Epirubicin Combined with CVP ± Rituximab (High-dose Epirubicin Combined with CVP ± Rituximab)

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
CGTBiologicstaleImmune Cell, Inc.Phase 1

ICAR30 T cells (ICAR30 T cells)

Hodgkin Lymphoma; Anaplastic Large Cell Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
AntibodystaleChinese Academy of Medical Scie…Phase 2

Ibrutinib Combined With Rituximab (Ibrutinib Combined With Rituximab)

DLBCL; MYD88 Gene Mutation · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
CGTBiologicstaleShenzhen Geno-Immune Medical In…Phase 2

Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20 (Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20)

CD19 Negative B-cell Malignancies · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleDonghua ZhangPreclinical

Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies (Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies)

Relapsed/Refractory B-cell Malignancies · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
ADCBiologicstalePfizerPhase 3

INO (Inotuzumab ozogamicin, Inotuzumab ozogamicin (INO))

B-Cell Acute Lymphoblastic Leukaemia · B-Cell Acute Lymphoblastic Leukaemia

#B-CellAcuteLymphoblasticLeukaemi#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstalePfizerApproved

Inotuzumab ozogamicin-dose level 1 (Inotuzumab ozogamicin-dose level 1)

Leukemia; Precursor b-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia

#Leukemia#ADC#Approved#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
CGTBiologicstaleWenbin QianPhase 2

Interleukin-7 and Chemokine (C-C Motif, Interleukin-7 and Chemokine, Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells)

B Cell Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleChongqing Precision Biotech Co.…Phase 1

Invivo CAR-T (Invivo CAR-T)

B-Acute Lymphoblastic Leukemia; B Cell Non-Hodgkin's Lymphoma · B-Acute Lymphoblastic Leukemia

#B-AcuteLymphoblasticLeukemia#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING

24 / 33 페이지

← 이전다음 →